Still, more than half of Americans don’t plan to get a Covid booster this year, according to a recent Pew Research Center ...

The third scenario, in which the booster dose was with the Pfizer vaccine, showed the highest percentages of effectiveness: 56.8% against symptomatic infections and 85.5% against severe cases.

Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.

The phase 2 trial will test a 30 µg dose of the shot in around 200 adult volunteers in the US who have already received one booster dose at least 90 days before enrolment, said Pfizer.

A new study claims Pfizer Covid-19 vaccines contain DNA contamination levels exceeding regulatory safety limits by up to 470 ...

Queenslanders are so fed up with almost five years of Covid-19 that uptake of the newest booster shot is poor, contributing ...

Older Australians and anyone eligible for a booster can benefit from getting the latest COVID-19 vaccine before an expected festive season wave.The ...

Pfizer's fundamentals are improving, with solid Q3 earnings, upgraded 2024 guidance, and a strategic pivot towards the fast-growing oncology market. The stock is undervalued with a 32% upside ...

Pfizer stock (NYSE: PFE) is down 7% in a month, amid rising concerns over the future of vaccines under Robert F. Kennedy Jr. in the new government, given the perception of him being a prominent ...